Australian University Rankings Guide

Contrast Media and Molecular Imaging (ERA Journal)

Contrast Media and Molecular Imaging is an ERA accredited research journal used as part of the evaluation of the ERA research rankings.

Contrast Media and Molecular Imaging issns are issn1: 1555-4309 issn2: 1555-4317.

The fields covered by Contrast Media and Molecular Imaging as part of the evaluation of Australian university research excellence are:

Medicinal and Biomolecular Chemistry Research Rankings (Sub-Field)

Biomedical Engineering Research Rankings (Sub-Field)

Medical Biotechnology Research Rankings (Sub-Field)

Other ERA-accredited journals supporting the evaluation of the Medicinal and Biomolecular Chemistry field include:

- Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry
- Biochemical and Biophysical Research Communications
- Bioorganic and Medicinal Chemistry
- ChemBioChem: a European journal of chemical biology
- International Journal of Bioscience Biochemistry and Bioinformatics (IJBBB)
- Journal of Biophotonics
- Journal of Cancer Biology and Research
- Journal of Computer-Aided Molecular Design
- Journal of Environmental and Analytical Toxicology
- Journal of Enzyme Inhibition and Medicinal Chemistry
- Journal of Molecular Medicine
- Magnetic Resonance in Chemistry
- Mini-Reviews in Medicinal Chemistry
- Molecules
- Organic Preparations and Procedures International: the new journal for organic synthesis

ERA Research Rankings Submenu

- ERA 2018 Outcomes Research Rankings List

- ERA 2018 Research Rankings Analysis

- ERA 2018 Individual University Outcomes List

- ERA List of Research Fields Rankings

- ERA Journal Rankings 2018 List

Latest News and Updates:

- Top 10 Best Australian Universities

- Gender Balance Male-Female Ratio

- ERA 2018 Outcomes Research Rankings List

- University Bachelor Degree Completion Rates

- QS Employability Rankings Australian Universities

- ARWU World Rankings of Australian Universities

- Group of Eight (go8) World Rankings

Share This Page

  • Share on Facebook1
  • Share on Twitter2
  • Share on Linkedin3
  • Share on Reddit4